Kornimate/medical-research-clean huggingface dataset:
prevalence of post traumatic stress disorder related to diabetes diagnosis or severe hypoglycaemia in adult with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: in france, the adult population living with diabetes in 2016 is estimated at more than 3.3 million patients treated. type 1 diabetes (t1dm) represents 5.6% of diabetic patients (approximately 185,000 patients). numerous studies show that patients fear hypoglycemia, with an impact on their quality of life, sleep disorders and depressive symptoms. in addition, there is a metabolic impact with a problem of therapeutic compliance and an alteration of glycemic control. this study examine the relation between post traumatic stress disorder (ptsd) and diabetes diagnosis or severe hypoglycaemia in adults with type 1 diabetes. the aim of this study is to evaluate the prevalence of ptsd in this population.


Eligibility criteria:
inclusion criteria: * 18 years of age or older, * with type 1 diabetes, * willing and able to complete all the questionnaires in french, * who have given oral consent, * being affiliated to a social security scheme or being a beneficiary of such a scheme. exclusion criteria: * non-diabetic type 1, * with an unstable psychiatric pathology, * pregnant or breastfeeding women, * subject to a measure for the protection of justice, * having opposed the research.
a randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial was conducted in europe,asia and africa. study participants were randomised evenly to treatment with semaglutide (0.1 mg qw - 1.6 mg qw, 6 treatment arms, placebo or liraglutide (1.2 mg qd, or 1.8 mg qd).treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.primary efficacy parameter was hba1c and the treatment duration was 12 weeks.


Eligibility criteria:
inclusion criteria: * men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months * stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months * hba1c: 7.0-10.0 % (both inclusive) * body weight between 60 kg and 110 kg exclusion criteria: * treatment with insulin, glp-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, alpha-gis, or any investigational drug, within the last three months * impaired liver or kidney function * proliferative retinopathy or maculopathy requiring acute treatment * clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension * recurrent major hypoglycaemia or hypoglycaemic unawareness * present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)
pharmacokinetic comparison of vitamin's d2 and d3 in stage 5 chronic kidney disease patients on chronic hemodialysis

Conditions: Chronic Kidney Disease

Summary: the purpose of this study is to compare the pharmacokinetic 25(oh)d and 1,25(oh)2d responses to a single oral dose of vitamin d2 or vitamin d3 in a group of stage 5-chronic kidney disease subjects requiring chronic hemodialysis.

this is a randomized, single blind, controlled study. subjects will be randomly assigned to receive 1) placebo capsules (control group); 2) capsules with ergocalciferol (the vitamin d2 group); or 3) capsules with cholecalciferol (the vitamin d3 group).

Eligibility criteria:
inclusion criteria: * 30 men and women, ages 20-65, bmi 18-30, requiring chronic hemodialysis exclusion criteria: * they will habitually consume less than 16 oz of milk per day and get less than 10 hours of sun exposure per week. we will exclude those with granulomatous conditions, cirrhotic liver disease, and those taking anticonvulsants, barbiturates, or steroids in any form or any investigational drugs within 4 weeks. we will exclude those with pregnancy or planned pregnancy, hypercalcemia (\>10.4 mg/dl) previously recorded, chronic gi disease which would interfere with absorption, any allergy to vitamin d3, or chronic vitamin d intake \>1,000 iu daily. subjects will continue to take a calcitriol analogue and phosphorus binder as prescribed by their nephrologist. calcitriol analogues are to be documented and remain constant throughout study.

Keywords: chronic kidney disease
establishing and eliminating cue-drug associations in human cocaine addiction

Conditions: Cocaine Dependent Subjects

Summary: we will develop a procedure for conditioning cue-cocaine associations in human drug users. next, we will reactivate that learning and intervene pharmacologically to prevent the reconsolidation of cue-drug memories. we hypothesize that a combined behavioral and pharmacological approach will have significant potential for persistently inhibiting relapse.


Eligibility criteria:
inclusion criteria: 1. age 18 - 50 years 2. voluntary, written, informed consent 3. physically healthy by medical history, physical, neurological, ecg, and laboratory examinations 4. dsm-iv criteria for cocaine abuse (305.60) or cocaine dependence (304.20) 5. recent street cocaine use in excess of that administered in the current study 6. intravenous and/or smoked (crack/freebase) use 7. positive urine toxicology screen for cocaine 8. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (-hcg) test 9. able to read english and complete study evaluations. exclusion criteria: 1. other drug dependence (except nicotine) 2. a primary major dsm-iv psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine 3. a history of significant medical (cardiovascular) or neurological illness (e.g., prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrythmias of clinical significance, and/or need for cardiovascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures) 4. current use of psychotropic and/or potentially psychoactive prescription medication 5. seeking treatment for drug abuse/dependence 6. those having contraindications to beta-blocker administration, including diagnoses of asthma, bronchitis, emphysema, or a history of adverse reactions to beta-blockers (including propranolol), as well as those with bradycardia and/or first-degree or greater heart block by ecg
effect of an aquatic exercise program in patients with chronic low back pain

Conditions: Chronic Low-back Pain; Muscle Atrophy; Diagnostic Imaging; Exercise Therapy

Summary: the goal of this pilot randomized controlled trial is to compare the effects of aquatic therapy versus standard care on paraspinal and gluteal morphology and function in individuals with chronic low back pain.the main questions it aims to answer are: 1. what are the effects of aquatic therapy versus standard care on a) paraspinal and gluteal muscle size, composition (e.g., fatty infiltration) and b) lumbar and gluteal muscle strength in individuals with chronic lbp? 2. is aquatic therapy more effective than standard care to improve pain, function and psychological factors (e.g., kinesiophobia, catastrophizing, anxiety, and depression)? 3. is using a digital application "play the pain" feasible to monitor pain levels and the activities that participants used to cope with pain? participants will be assigned to either the aquatic therapy group or standard care group where they will undergo a 10-week intervention including two 60-minute session per week.


Eligibility criteria:
inclusion criteria: 1. chronic nonspecific lbp (\>3 months), defined as pain in the region between the lower ribs and gluteal folds, with or without leg pain 2. currently seeking care for lbp 3. aged between 18 and 65 years old 4. english or french speakers 5. have a score of "moderate" or "severe" disability on the modified oswestry low back questionnaire 6. do not currently engaged in sports or fitness training specifically for the lower back muscles (3 months prior the beginning of the trial). exclusion criteria: 1. evidence of nerve root compression or reflex motor signs deficits 2. previous spinal surgery or vertebral fractures 3. other major lumbar spine structural abnormalities 4. comorbid health conditions that would prevent active participation in exercise programs

Keywords: low back pain musculoskeletal rehabilitation aquatic therapy standard care diagnostic imaging muscle morphology randomized controlled trial
predictive analytics in lower respiratory tract infections (va-lrtis)

Conditions: Ventilator-Associated Event

Summary: to determine the accuracy and generalizability of va-lrti algorithm to detect and predict three high-incidence and high-impact vaes from electronic health records data: 1) ventilator-associated event, 2) ventilator-associated pneumonia, and 3) ventilator-associated tracheobronchitis.


Eligibility criteria:
all invasively ventilated icu patient (aged 18 or over)
optilene® suture for coronary artery bypass graft surgery

Conditions: Coronary Heart Disease; Multi Vessel Coronary Artery Disease

Summary: the study is a voluntary study, initiated by b. braun to collect clinical data for optilene® suture concerning its key indication.

coronary artery bypass graft (cabg) surgery is one of the most common elective surgical procedure. in total 40.000 cabg´s have been performed yearly in germany in 2012 and 2013 which presents 60% of all cardiac surgical interventions. coronary artery bypass grafting is performed for patients with coronary artery disease (cad) to improve quality of life and to reduce cardiac-related mortality. cad is the most leading cause of mortality in the western world as well as in developing countries and it is the most common cause of heart failure. cabg was introduced in the 1960s. cabg operation has become the most studied intervention in the history of surgery. it is highly effective in the treatment of severe angina and it delays unfavorable events such as death, myocardial infarction and recurrence of angina in comparison to other treatment forms. there is a general agreement that already in the early postoperative period cabg surgery improves the disease in patients with symptomatic left main coronary artery stenosis or stenosis of the three main coronary vessels.

Eligibility criteria:
inclusion criteria: * patients undergoing an elective primary coronary artery bypass graft surgery (cabg). * on pump or off pump cabg surgery * age ≥25 years * written informed consent exclusion criteria: * emergency surgery * insulin dependent diabetes mellitus * acute myocardial infarction with creatinine kinase-mb level \> 10% of ck and /or ecg signs * known immunodeficiency or immunosuppression * other combined aortic valve intervention except cardiac valve or mitral valve surgery * participation or planned participation in another cardiovascular study before study follow-up is completed. * inability to give informed consent due to mental condition, mental retardation, or language barrier.

Keywords: cabg coronary artery bypass grafting
skin wetting in burn survivors

Conditions: Burn Injury

Summary: this project will identify the efficacy of whole body skin wetting aimed to attenuate excessive elevations in internal body temperatures during physical activity in well-healed burn survivors. the investigators will conduct a randomized crossover design study. non-burned control subjects, subjects who experienced burns covering \~20% to 40% of their body surface area, and subject having burns \>40% of their body surface area will be investigated. subjects will exercise in heated environmental conditions while receiving no cooling or whole body skin wetting.


Eligibility criteria:
inclusion criteria: non-burn survivors * healthy male and female subjects * 18-65 years of age. * free of any underlying medical conditions exclusion criteria (non-burned individuals): * any burn-related injuries resulting in at least one night of hospitalization. * heart disease or any other chronic medical condition requiring regular medical therapy including cancer, diabetes, and hypertension. * abnormalities detected on routine screening * individuals who participate in a structured aerobic exercise training program at moderate to high intensities. * current smokers, as well as individuals who regularly smoked within the past 3 years. * body mass index of greater than 30 kg/m\^2. * pregnant individuals inclusion criteria (burn survivors): * healthy male and female subjects * 18-65 years of age. * free of any underlying medical conditions * having a burn injury covering 20-40% or \>40% of the participant's body surface area; at least 50% of those burn injuries must be full thickness that required skin grafting. * participants must have been hospitalized due to the burn injury for a minimum of 15 days exclusion criteria (burn survivors): * any burn-related injuries resulting in at least one night of hospitalization. * heart disease or any other chronic medical condition requiring regular medical therapy including cancer, diabetes, and hypertension. * abnormalities detected on routine screening * individuals who participate in a structured aerobic exercise training program at moderate to high intensities. * current smokers, as well as individuals who regularly smoked within the past 3 years. * body mass index of greater than 30 kg/m\^2. * pregnant individuals * extensive unhealed injured skin
study of medication patch to treat children ages 6-12 with adhd

Conditions: ADHD; Attention Deficit Hyperactivity Disorder

Summary: the purpose of this study is to investigate the effectiveness of a medication skin patch called methylphenidate transdermal system (mts). we will compare the mts medicated patch to a placebo patch. we want to find out how well it treats adhd during the early morning hours before a child leaves for school or summertime routines.


Eligibility criteria:
inclusion criteria: * male and female outpatients 6 to 12 years of age. * diagnosis of attention deficit hyperactivity disorder (adhd), by dsm-iv, as manifested in clinical evaluation and confirmed by structured interview. * participation in structured morning routine (e.g. school, camp, or other organized activities). exclusion criteria: * mental retardation (iq \<75). * subjects with a medical condition, or treatment that will either jeopardize subject safety or affect the scientific merit of the study. * subjects with moderate to severe dermatological atopy. * subjects with known structural cardiac abnormalities. * organic brain disorders. * seizure disorder. * subjects with tourette's syndrome, or a history of psychosis or bipolar disorder. * subjects with current comorbid psychopathology that in the investigator's opinion will warrant immediate treatment or will interfere with the safe execution of the protocol (i.e. anxiety or major depressive disorder rated as moderate on cgi). * subjects with a history of intolerable adverse effects or non-response to methylphenidate. * pregnant or nursing females.

Keywords: adhd attention deficit hyperactivity disorder daytrana mts patch methylphenidate transdermal system
honey as a wound care modality in treating deep neck space abscess

Conditions: Neck Abscess

Summary: this study investigates the effectiveness of honey as a treatment for deep neck space abscesses, comparing it to standard wound care methods. conducted as a randomized clinical trial, it aims to determine whether honey can offer a viable alternative or improvement in managing this condition. the research assesses outcomes related to healing, infection control, and overall patient recovery.

deep neck abscess is one of the diseases in the field of otorhinolaryngology-head and neck surgery that has high morbidity, mortality, and costs. management of deep neck abscesses involves incision and drainage, abscess exploration, systemic administration of broad-spectrum antibiotics, management of comorbid factors, and postoperative wound care until healing. standard dressing for wound care has been time-consuming and costly. honey is one type of dressing modality that has been widely used in wound care for various parts of the body and diseases. honey is expected to be a more cost-efficient treatment modality that supports accelerated wound healing, leading to better outcomes and cost savings. the research design used is a single-blind randomized controlled trial (rct), where researchers randomly assign one intervention to respondents to compare the effects of honey and prontosan on the wound healing process. the population and sample of the study include all patients with deep neck abscesses treated at dr. sardjito general hospital, the teaching hospital of the faculty of medicine gadjah mada university and other hospitals equipped with board-certified otorhinolaryngologists. the participants in the control group were treated with standard dressing, while participants in the study group were treated with standard dressing along with honey dressing.

Eligibility criteria:
inclusion criteria: * deep neck abscess patients over 18 years old with or without comorbidities except for malignant diseases exclusion criteria: * patients who refused intervention * patients who underwent vacuum-assisted closure (vac) * patients with incomplete medical records

Keywords: deep neck space infection deep neck space abscess wound healing honey dressing bates jensen wound assessment tool
aldosterone blockade in heart failure

Conditions: Heart Failure

Summary: heart failure causes significant morbidity and mortality and is the most rapidly increasing cardiovascular diagnosis in north america overall prevalence is estimated at 0.4% to 2.4%. recently, heart failure with a preserved ejection fraction (hfnef) was found in up to 50% of patients with symptomatic heart failure. many studies have demonstrated that hfnef has a poor prognosis with a mortality rate of up to 8% per year and a 50% chance of needing to be admitted to hospital in the next year. there are no proven therapies for this type of heart failure. aldosterone blockers (these drugs block a hormone that is elevated in patients with heart failure) are used in other types of heart failure. our goal is to see if this type of drug improves the function of the heart by looking at the thickness of the heart muscle using mri. also we will measure the amount of tissue formation and breakdown in the heart. the trial will be done using both the drug and a placebo so that we can see what effects are due to the drug.

aldosterone antagonists have shown efficacy in systolic heart failure and in patients with post-myocardial infarction systolic dysfunction in three major randomized placebo controlled trials. together these trials have demonstrated a reduction in mortality, hospitalization and a regression in left ventricular mass by mri. primary objective the primary objective of this study will be to assess the change in markers of collagen turnover and correlate this with specific measures of left ventricular mass regression and diastolic function on mri after 4 months of aldosterone blockade. study design and methods this study is a double-blind, concealed allocation, randomized trial at the university of alberta where patients with diastolic heart failure will be randomized to spironolactone or matching placebo for 4 months. outcomes assessed include lv mass by mri, collagen markers, other biomarkers, clinical outcomes, quality of life and exercise testing

Eligibility criteria:
inclusion criteria: 1. hf by framingham criteria 2. at least one admission to hospital for hf within the last 180 days 3. new york heart association class ii thru iv 4. echocardiographic criteria:at least moderate diastolic dysfunction, ejection fraction \>45% exclusion criteria: 1. creatinine clearance \<40 mls/min/1.73m2 2. potassium \>5.0 mmol/l 3. recent acute coronary syndrome in the prior 4 weeks 4. planned revascularization, defibrillator or pacemaker in next 4 months 5. known previous intolerance to aldosterone antagonist

Keywords: heart failure collagen diastolic function
ccta to optimize the diagnostic yield of invasive angiography

Conditions: Coronary Artery Disease

Summary: this study aims to reduce patient risk and costs to the healthcare system by improving the diagnostic yield of invasive coronary angiography through existing triage processes to improve risk stratification using coronary computed tomographic angiography (ccta) as a first step in low risk patients. all low-risk patients referred for invasive coronary angiography will be potentially eligible for ccta instead of invasive angiography as a first-line diagnostic test. all cctas will be read by both a level 3-trained cardiologist and a radiologist. the results of the ccta, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged by the hiu triage, only when clearly indicated


Eligibility criteria:
inclusion criteria: 1. non urgent outpatient referral 2. canadian cardiovascular society class i or ii 3. indication for invasive angiogram includes: rule out coronary artery disease (cad) and cardiomyopathy exclusion criteria: 1. age \ 65 years old or women \>75 years old 2. patient refusal to provide verbal consent for ccta at time of triage contact or unable to provide informed consent 3. referring physician refusal for their eligible patients to be approached for the cardia study 4. any prior ccta 5. atrial fibrillation 6. creatinine \> 150 mmol/l 7. diabetes mellitus 8. high risk exercise stress test or functional imaging 9. known severe valvular disease being considered for valve surgery 10. any known cad * prior acute coronary syndrome (acs) * prior percutaneous coronary intervention (pci) or coronary artery bypass graft (cabg)

Keywords: angiogram, coronary computed tomographic angiography